Drug for Primary Biliary Cholangitis Looks Promising After Positive Results in a Phase 3 Trial
Just over half (51%) of patients who treated with the experimental agent, called elafibranor, achieved a biochemical response compared with only 4% of those patients randomly assigned to placebo.
Investigating the Protein Dose-Sparing Effect of AS01B Adjuvant in a Subtype C gp120 HIV Vaccine Trial
The same adjuvant is part of Shingrix, the shingles vaccine.
Positive Results for Resmetirom for Nonalcoholic Fatty Liver Disease
The FDA has set March 24, 2024, as PDUFA date for the drug.
Community-Based, Point-of-Diagnosis Hepatitis C Treatment Improves Outcomes
Researchers at the University of California, San Francisco, report positive results from the No One Waits study.
The Rise of Autoimmune Hepatitis Worldwide: A Closer Look
Uncovering the Hidden Potential: CAMs as a Game-Changer in HBV Treatment
Capsid assembly modulators (CAM) work by assembling flawed hepatitis B capsids and preventing the formation of new infectious viruses.
Hepatitis D Elimination: Progress, Opportunities, and Challenges
Gilead’s hepatitis D antiviral, bulevirtide, was dealt a setback last year when the FDA issued a complete response letter. Positive results from a phase 3 trial of bulevirtide, were reported in July.
Beyond 'Nonalcoholic' and 'Fatty': The Evolution of NAFLD Terminology
To add precision to the nomenclature and nosology and remove stigma, experts are moving to rename nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease.
Promising Trial Results for Pegozafermin for NASH
Based on the results published in the New England Journal of Medicine, the FDA has granted breakthrough status to the FGF21 analogue. The drug's maker is planning a phase 3 trial.
2 Clarke Drive Cranbury, NJ 08512